Beilu Pharmaceutical: Announcement of Beijing Beilu Pharmaceutical Co., Ltd. on the revision of the plan for issuance of stocks to specific objects through simplified procedures in 2025
Stock code: 300016 Stock abbreviation: Beilu Pharmaceutical Announcement number: 2025-125
Beijing Beilu Pharmaceutical Co., Ltd.
Announcement on the Revised Explanation of the Plan for Issuing Stocks to Specific Targets through Simple Procedures in 2025
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Beijing Beilu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 2024 shareholders' meeting on May 8, 2025, and reviewed and approved the "Proposal on Requesting the Shareholders' Meeting to Authorize the Board of Directors to Issue Stocks to Specific Objects through Simple Procedures"; the fourth meeting of the ninth board of directors was held on September 25, 2025, and the issuance plan and other issuance-related matters were reviewed and approved.
On December 23, 2025, the company held the seventh meeting of the ninth board of directors, which reviewed and approved the "Proposal on the Company's Plan for Issuing Stocks to Specific Objects through Simple Procedures in 2025 (Revised Draft)" and other proposals related to this issuance, and accordingly revised the plan for issuance of stocks to specific objects through simplified procedures. The main revisions are as follows:
Plan Chapter Contents Revision Status
Updated the review status of matters related to this issuance, the amount of funds raised and important event reminders Important event reminders
way
Table of Contents Table of Contents The page numbers of the corresponding table of contents chapters have been adjusted according to the contents of this plan (revised draft). Interpretation The reporting period of this issuance has been updated.
2. Background and
Updated background and purpose of this release
purpose
4. This time, we will apply for simple procedures
Section 1 This post
Stock issuance plan for specific targets Updated the amount and use of funds raised from this issuance
Line overview
Summary
8. Approval process for this issuance
Updated approval procedures performed for this issuance
preface
Section 2 Board of Directors 1. Use of funds raised this time
Updated the amount and use of funds raised from this issuance
About this fundraising plan
Feasibility of use of funds 2. Investment of funds raised this time According to the updated use plan of funds raised this time, the funds raised this time have been updated.
Analyze the specific situation of the project The specific situation of the financial investment project
Section 3 Board of Directors 6. Related to this stock issuance
Updated data from January to September 2025
Description of the risks of this issuance
Plan Chapter Contents Revision Status
Discussion of corporate impact
and analysis
Section 5 and this issue 2. This issuance is diluted immediately
Directors related to the issuance risk warning and filling of returns. Updated statements and commitments regarding the impact of this issuance of diluted current returns on the company's main financial indicators. Return measures, as well as commitments made by relevant entities and the relationship between the investment projects with funds raised and the company's existing business.
According to the authorization of the company's 2024 annual shareholders' meeting, this amendment does not need to be submitted to the company's shareholders' meeting for review. For details, please refer to the relevant announcement disclosed by the company on the same day on Juchao Information Network (www.cninfo.com.cn), the GEM information disclosure website designated by the China Securities Regulatory Commission.
Announcement is hereby made.
Beijing Beilu Pharmaceutical Co., Ltd. Board of Directors
December 23, 2025